EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL

Marco V Haselager iD, Rachel Thijssen iD, Danique Bax, Demi Both, Francien De Boer, Simon Mackay, Julie Dubois, Clemens Mellink, Arnon P Kater, Eric Eldering iD

Molecular Oncology · 2023

DOI: 10.1002/1878-0261.13364 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2023. Verfasst von Marco V Haselager und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Immunology, Amsterdam UMC location University of Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, NF-kappa B. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Blaauboer Fund via the AMC foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preventing or overcoming resistance to the Bcl‐2 inhibitor venetoclax is an emerging unmet clinical need in patients with chronic lymphocytic leukaemia (CLL). The upregulation of anti‐apoptotic Bcl‐2 members through signalling pathways within the tumor microenvironment appears as a major factor leading to resistance to venetoclax. Previously, we reported that T cells can drive resistance through CD40 and non‐canonical NF‐κB activation and subsequent Bcl‐XL induction. Moreover, the T cell‐derived cytokines IL‐21 and IL‐4 differentially affect Bcl‐XL expression and sensitivity to venetoclax via unknown mechanisms. Here, we mechanistically dissected how Bcl‐XL is regulated in the context of JAK–STAT signalling in primary CLL. First, we demonstrated a clear antagonistic role of IL‐21/STAT3 signalling in the NF‐κB‐mediated expression of Bcl‐XL, whereas IL‐4/STAT6 further promoted the expression of Bcl‐XL. In comparison, Bfl‐1, another NF‐κB target, was not differentially affected by either cytokine. Second, STAT3 and STAT6 affected Bcl‐XL transcription by binding to its promoter without disrupting the DNA‐binding activity of NF‐κB. Third, in situ proximity ligation assays (isPLAs) indicated crosstalk between JAK–STAT signalling and NF‐κB, in which STAT3 inhibited canonical NF‐κB by accelerating nuclear export, and STAT6 promoted non‐canonical NF‐κB. Finally, NF‐κB inducing kinase (NIK) inhibition interrupted the NF‐κB/STAT crosstalk and resensitized CLL cells to venetoclax. In conclusion, we uncovered distinct crosstalk mechanisms that shape the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL, thereby revealing new potential therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellNF-kappa BHumansApoptosisDrug Resistance, NeoplasmInterleukin-4Proto-Oncogene Proteins c-bcl-2Tumor MicroenvironmentSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

chronic lymphocytic leukaemiadrug resistancemicroenvironmentsignalling

Substanzen

Interleukin-4NF-kappa BProto-Oncogene Proteins c-bcl-2venetoclaxSulfonamidesBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Department of Experimental Immunology, Amsterdam UMC location University of Amsterdam, The Netherlands.
  • Amsterdam institute for Infection & Immunity, The Netherlands.
  • Cancer Immunology, Cancer Center Amsterdam, The Netherlands.
  • Lymphoma and Myeloma Center Amsterdam, LYMMCARE, Amsterdam, The Netherlands.
  • Department of Hematology, Amsterdam UMC location University of Amsterdam, The Netherlands.
  • Ikazia Ziekenhuis, Rotterdam, The Netherlands.

ORCID-Profile: Marco V Haselager, Rachel Thijssen, Eric Eldering

Förderung

  • Blaauboer Fund via the AMC foundation

Zitieren

APA

Haselager, M. V., Thijssen, R., Bax, D., Both, D., De Boer, F., Mackay, S., Dubois, J., Mellink, C., Kater, A. P., & Eldering, E. (2023). JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL. Molecular Oncology. https://doi.org/10.1002/1878-0261.13364

Vancouver

Haselager MV, Thijssen R, Bax D, Both D, De Boer F, Mackay S, et al. JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL. Molecular Oncology. 2023. doi:10.1002/1878-0261.13364

BibTeX
@article{Haselager2023,
  author = {Haselager, Marco V and Thijssen, Rachel and Bax, Danique and Both, Demi and De Boer, Francien and Mackay, Simon and Dubois, Julie and Mellink, Clemens and Kater, Arnon P and Eldering, Eric},
  title = {JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL},
  journal = {Molecular Oncology},
  year = {2023},
  doi = {10.1002/1878-0261.13364}
}
Kostenlos starten →